Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol 1990;83(3):149-51
Date
01/01/1990Pubmed ID
2109455DOI
10.1159/000205193Scopus ID
2-s2.0-0025270769 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
A patient whose chronic myelogenous leukemia (CML) was treated with interferon alpha (IFN-alpha) is described. The disease showed karyotypic evolution during the chronic phase and the later myeloid acceleration. Both of these secondary clonal phenomena responded to IFN-alpha dose escalation. The case illustrates the dose dependence of CML responses to IFN-alpha. The phenomenon of clonal evolution is discussed in the context of this patient's disease.
Author List
Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz MAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Clone CellsHumans
Interferon Type I
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged